Washington [US], April 15: U.S. Supreme Court Justice Samuel Alito temporarily halted lower court rulings that set limits on access to the abortion pill mifepristone.
This will give the nation's top judicial body time to weigh a bid by President Joe Biden's administration to defend the drug amid a challenge by anti-abortion groups.
The action by the conservative justice, who handles emergency matters arising from a group of states including Texas, freezes the litigation and maintains the current availability of mifepristone pending a further order from himself or the entire court.
The U.S. Justice Department and Danco Laboratories, the pill's manufacturer, filed emergency requests earlier on Friday asking the justices to freeze an April 7 preliminary injunction by Texas-based U.S. District Judge Matthew Kacsmaryk that would greatly restrict mifepristone's distribution while litigation contesting its federal regulatory approval proceeds.
Alito acted just hours before the restrictions were due to have taken effect. He directed the challengers to respond by Tuesday to the requests by the Justice Department and Danco, while delaying the restrictions from taking effect until 11:59 p.m. EDT (0359 GMT) on Wednesday. The court would be expected to issue another order on the issue by that time.
The administration is seeking to defend the availability of mifepristone in the face of mounting abortion bans and restrictions enacted by Republican-led states since the Supreme Court in June 2022 overturned the landmark 1973 Roe v. Wade decision that had legalized the procedure nationwide. Alito authored that ruling for the court, which has a 6-3 conservative majority.
The administration and Danco told the justices in their filings that mifepristone might not be available for months if the restrictions were allowed to take effect.
Mifepristone, approved by the U.S. Food and Drug Administration in 2000, is used in combination with another drug called misoprostol to perform medication abortions, which account for more than half of all U.S. abortions. The FDA is the U.S. agency that signs off on the safety of food products, drugs and medical devices.
The Justice Department said the lower court orders issued in the past week limiting mifepristone's availability would have "sweeping consequences" for women who need access to it and the FDA's scientific judgment authority over drug safety.
Danco said it may be forced to halt operations in the face of regulatory uncertainty.
Source: Fijian Broadcasting Corporation